The Use of Hyaluronidase in Aesthetic Practice: A Comparative Study of Practitioner Usage in Elective and Emergency Situations

• Published in: Aesthetic surgery journal 2024-05, Vol.44 (6), p.647-657
• Main Authors: Currie, Elena, Granata, Bronwyn, Goodman, Greg, Rudd, Alice, Wallace, Katy, Rivkin, Alexander, Hart, Sarah, Porter, Catherine E, Harris, Steven, Walker, Lee, Lin, Frank, Corduff, Niamh, Davies, Nik, Roberts, Stefania, Clague, Michael, Callan, Peter P, McDonald, Cara, Magnusson, Mark, Tsirbas, Angelo, Gupta, Ritu, Bekhor, Philip, Welsh, Belinda
• Format: Article
• Language: English
• Subjects: Anaphylaxis - chemically induced; Cosmetic Techniques - adverse effects; Dermal Fillers - administration & dosage; Dermal Fillers - adverse effects; Editor's Choice; Humans; Hyaluronic Acid - administration & dosage; Hyaluronic Acid - adverse effects; Hyaluronoglucosaminidase - administration & dosage; Original; Practice Patterns, Physicians' - statistics & numerical data; Surveys and Questionnaires - statistics & numerical data
• ISSN: 1090-820X; 1527-330X
• DOI: 10.1093/asj/sjae009

Hyaluronic acids (HAs) continue to be the fillers of choice worldwide and their popularity is growing. Adverse events (AEs) are able to be resolved through the use of hyaluronidase (HYAL). However, routine HYAL use has been at issue due to perceived safety issues. There are currently no guidelines on the use of HYAL in aesthetic practice, leading to variability in storage, preparation, skin testing, and beliefs concerning AEs. This manuscript interrogated the use of this agent in daily practice. A 39-question survey concerning HYAL practice was completed by 264 healthcare practitioners: 244 from interrogated databases and 20 from the consensus panel. Answers from those in the database were compared to those of the consensus panel. Compared to the database group, the consensus group was more confident in the preparation of HYAL, kept reconstituted HYAL for longer, and was less likely to skin test for HYAL sensitivity and more likely to treat with HYAL in an emergency, even in those with a wasp or bee sting anaphylactic history. Ninety-two percent of all respondents had never observed an acute reaction to HYAL. Just over 1% of respondents had ever observed anaphylaxis. Five percent of practitioners reported longer-term adverse effects, including 3 respondents who reported loss of deep tissues. Consent before injecting HA for the possible requirement of HYAL was always obtained by 74% of practitioners. Hyaluronidase would appear to be an essential agent for anyone injecting hyaluronic acid filler. However, there is an absence of evidence-based recommendations with respect to the concentration, dosing, and treatment intervals of HYAL, and these should ideally be available.